186 related articles for article (PubMed ID: 36547689)
1. Monalizumab efficacy correlates with HLA-E surface expression and NK cell activity in head and neck squamous carcinoma cell lines.
Lee J; Keam B; Park HR; Park JE; Kim S; Kim M; Kim TM; Kim DW; Heo DS
J Cancer Res Clin Oncol; 2023 Aug; 149(9):5705-5715. PubMed ID: 36547689
[TBL] [Abstract][Full Text] [Related]
2. Cetuximab therapy in head and neck cancer: immune modulation with interleukin-12 and other natural killer cell-activating cytokines.
Luedke E; Jaime-Ramirez AC; Bhave N; Roda J; Choudhary MM; Kumar B; Teknos TN; Carson WE
Surgery; 2012 Sep; 152(3):431-40. PubMed ID: 22770960
[TBL] [Abstract][Full Text] [Related]
3. Immunogenomic correlates of response to cetuximab monotherapy in head and neck squamous cell carcinoma.
Faden DL; Concha-Benavente F; Chakka AB; McMichael EL; Chandran U; Ferris RL
Head Neck; 2019 Aug; 41(8):2591-2601. PubMed ID: 30828910
[TBL] [Abstract][Full Text] [Related]
4. An IL-15-based superagonist ALT-803 enhances the NK cell response to cetuximab-treated squamous cell carcinoma of the head and neck.
Pinette A; McMichael E; Courtney NB; Duggan M; Benner BN; Choueiry F; Yu L; Abood D; Mace TA; Carson WE
Cancer Immunol Immunother; 2019 Aug; 68(8):1379-1389. PubMed ID: 31338557
[TBL] [Abstract][Full Text] [Related]
5. Metformin increases natural killer cell functions in head and neck squamous cell carcinoma through CXCL1 inhibition.
Crist M; Yaniv B; Palackdharry S; Lehn MA; Medvedovic M; Stone T; Gulati S; Karivedu V; Borchers M; Fuhrman B; Crago A; Curry J; Martinez-Outschoorn U; Takiar V; Wise-Draper TM
J Immunother Cancer; 2022 Nov; 10(11):. PubMed ID: 36328378
[TBL] [Abstract][Full Text] [Related]
6. Combined IL6 and CCR2 blockade potentiates antitumor activity of NK cells in HPV-negative head and neck cancer.
Yang F; Yuan C; Chen F; Qin ZS; Schmitt NC; Lesinski GB; Saba NF; Teng Y
J Exp Clin Cancer Res; 2024 Mar; 43(1):76. PubMed ID: 38468260
[TBL] [Abstract][Full Text] [Related]
7. Memory-like Differentiation, Tumor-Targeting mAbs, and Chimeric Antigen Receptors Enhance Natural Killer Cell Responses to Head and Neck Cancer.
Jacobs MT; Wong P; Zhou AY; Becker-Hapak M; Marin ND; Marsala L; Foster M; Foltz JA; Cubitt CC; Tran J; Russler-Germain DA; Neal C; Kersting-Schadek S; Chang L; Schappe T; Pence P; McClain E; Zevallos JP; Rich JT; Paniello RC; Jackson RS; Pipkorn P; Adkins DR; DeSelm CJ; Berrien-Elliott MM; Puram SV; Fehniger TA
Clin Cancer Res; 2023 Oct; 29(20):4196-4208. PubMed ID: 37556118
[TBL] [Abstract][Full Text] [Related]
8. Anti-NKG2A mAb Is a Checkpoint Inhibitor that Promotes Anti-tumor Immunity by Unleashing Both T and NK Cells.
André P; Denis C; Soulas C; Bourbon-Caillet C; Lopez J; Arnoux T; Bléry M; Bonnafous C; Gauthier L; Morel A; Rossi B; Remark R; Breso V; Bonnet E; Habif G; Guia S; Lalanne AI; Hoffmann C; Lantz O; Fayette J; Boyer-Chammard A; Zerbib R; Dodion P; Ghadially H; Jure-Kunkel M; Morel Y; Herbst R; Narni-Mancinelli E; Cohen RB; Vivier E
Cell; 2018 Dec; 175(7):1731-1743.e13. PubMed ID: 30503213
[TBL] [Abstract][Full Text] [Related]
9. Interleukin-1 alpha increases anti-tumor efficacy of cetuximab in head and neck squamous cell carcinoma.
Espinosa-Cotton M; Rodman Iii SN; Ross KA; Jensen IJ; Sangodeyi-Miller K; McLaren AJ; Dahl RA; Gibson-Corley KN; Koch AT; Fu YX; Badovinac VP; Laux D; Narasimhan B; Simons AL
J Immunother Cancer; 2019 Mar; 7(1):79. PubMed ID: 30890189
[TBL] [Abstract][Full Text] [Related]
10. Cetuximab-induced natural killer cell cytotoxicity in head and neck squamous cell carcinoma cell lines: investigation of the role of cetuximab sensitivity and HPV status.
Baysal H; De Pauw I; Zaryouh H; De Waele J; Peeters M; Pauwels P; Vermorken JB; Smits E; Lardon F; Jacobs J; Wouters A
Br J Cancer; 2020 Sep; 123(5):752-761. PubMed ID: 32541873
[TBL] [Abstract][Full Text] [Related]
11. Assessment of the change in cetuximab-induced antibody-dependent cellular cytotoxicity activity of natural killer cells by steroid.
Kumai T; Oikawa K; Aoki N; Kimura S; Harabuchi Y; Kobayashi H
Head Neck; 2016 Mar; 38(3):410-6. PubMed ID: 25352398
[TBL] [Abstract][Full Text] [Related]
12. A phase II study of monalizumab in patients with recurrent/metastatic squamous cell carcinoma of the head and neck: The I1 cohort of the EORTC-HNCG-1559 UPSTREAM trial.
Galot R; Le Tourneau C; Saada-Bouzid E; Daste A; Even C; Debruyne P; Henry S; Zanetta S; Rutten A; Licitra L; Canon JL; Kaminsky MC; Specenier P; Rottey S; Guigay J; Kong A; Tinhofer I; Borcoman E; Dirix L; Raveloarivahy T; Fortpied C; Vanlancker M; Morfouace M; Govaerts AS; Machiels JP
Eur J Cancer; 2021 Oct; 158():17-26. PubMed ID: 34638090
[TBL] [Abstract][Full Text] [Related]
13. TLR8 stimulation enhances cetuximab-mediated natural killer cell lysis of head and neck cancer cells and dendritic cell cross-priming of EGFR-specific CD8+ T cells.
Stephenson RM; Lim CM; Matthews M; Dietsch G; Hershberg R; Ferris RL
Cancer Immunol Immunother; 2013 Aug; 62(8):1347-57. PubMed ID: 23685782
[TBL] [Abstract][Full Text] [Related]
14. Role of polymorphic Fc gamma receptor IIIa and EGFR expression level in cetuximab mediated, NK cell dependent in vitro cytotoxicity of head and neck squamous cell carcinoma cells.
López-Albaitero A; Lee SC; Morgan S; Grandis JR; Gooding WE; Ferrone S; Ferris RL
Cancer Immunol Immunother; 2009 Nov; 58(11):1853-64. PubMed ID: 19319529
[TBL] [Abstract][Full Text] [Related]
15. CD44v6 specific CAR-NK cells for targeted immunotherapy of head and neck squamous cell carcinoma.
Ciulean IS; Fischer J; Quaiser A; Bach C; Abken H; Tretbar US; Fricke S; Koehl U; Schmiedel D; Grunwald T
Front Immunol; 2023; 14():1290488. PubMed ID: 38022580
[TBL] [Abstract][Full Text] [Related]
16. CDX2 enhances natural killer cell-mediated immunotherapy against head and neck squamous cell carcinoma through up-regulating CXCL14.
Wang H; Nan S; Wang Y; Xu C
J Cell Mol Med; 2021 May; 25(10):4596-4607. PubMed ID: 33733587
[TBL] [Abstract][Full Text] [Related]
17. Down-regulation of HLA-B-associated transcript 3 impairs the tumoricidal effect of natural killer cells through promoting the T cell immunoglobulin and mucin domain-containing-3 signaling in a mouse head and neck squamous cell carcinoma model.
Yang J; Xiang J; Zhu M; Zhao Y; Zhou L; Hu B; Wang C
Immunobiology; 2022 Jan; 227(1):152127. PubMed ID: 34968777
[TBL] [Abstract][Full Text] [Related]
18. Natural killer cells have a synergistic anti-tumor effect in combination with chemoradiotherapy against head and neck cancer.
Jung EK; Chu TH; Vo MC; Nguyen HPQ; Lee DH; Lee JK; Lim SC; Jung SH; Yoon TM; Yoon MS; Cho D; Lee JJ; Cho HH
Cytotherapy; 2022 Sep; 24(9):905-915. PubMed ID: 35778350
[TBL] [Abstract][Full Text] [Related]
19. IL-15 and IL-2 increase Cetuximab-mediated cellular cytotoxicity against triple negative breast cancer cell lines expressing EGFR.
Roberti MP; Barrio MM; Bravo AI; Rocca YS; Arriaga JM; Bianchini M; Mordoh J; Levy EM
Breast Cancer Res Treat; 2011 Nov; 130(2):465-75. PubMed ID: 21308409
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of natural killer cell therapy combined with chemoradiotherapy in murine models of head and neck squamous cell carcinoma.
Jung EK; Chu TH; Kim SA; Vo MC; Nguyen VT; Lee KH; Jung SH; Yoon M; Cho D; Lee JJ; Yoon TM
Cytotherapy; 2024 Mar; 26(3):242-251. PubMed ID: 38142382
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
